Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
Sarepta Therapeutics (NASDAQ:SRPT) has appointed Deirdre P. Connelly to its Board of Directors, expanding the board to nine members, with eight being independent. Connelly brings over 30 years of pharmaceutical industry experience, having served as president of North America Pharmaceuticals for GlaxoSmithKline and president of U.S. Pharmaceutical Operations at Eli Lilly. Her extensive background includes executive roles in human resources and pharmaceutical operations.
Currently, Connelly serves on the boards of Macy's and Lincoln Financial Group, and is the Chairperson of the Board at Genmab A/B. This appointment aligns with Sarepta's strategy to deliver transformative therapies for rare diseases, leveraging Connelly's seasoned leadership and industry expertise.
Sarepta Therapeutics (NASDAQ:SRPT) ha nominato Deirdre P. Connelly nel suo Consiglio di Amministrazione, ampliando il consiglio a nove membri, di cui otto sono indipendenti. Connelly porta con sé oltre 30 anni di esperienza nell'industria farmaceutica, avendo ricoperto il ruolo di presidente della divisione farmaceutica per il Nord America di GlaxoSmithKline e presidente delle operazioni farmaceutiche negli Stati Uniti di Eli Lilly. Il suo ampio background include ruoli dirigenziali nelle risorse umane e nelle operazioni farmaceutiche.
Attualmente, Connelly è membro dei consigli di Macy's e Lincoln Financial Group ed è la Presidente del Consiglio di Genmab A/B. Questa nomina si allinea con la strategia di Sarepta di fornire terapie trasformative per malattie rare, sfruttando la leadership esperta e le competenze del settore di Connelly.
Sarepta Therapeutics (NASDAQ:SRPT) ha nombrado a Deirdre P. Connelly en su Junta Directiva, ampliando la junta a nueve miembros, de los cuales ocho son independientes. Connelly aporta más de 30 años de experiencia en la industria farmacéutica, habiendo sido presidenta de Farmacéuticos de América del Norte en GlaxoSmithKline y presidenta de Operaciones Farmacéuticas en EE. UU. en Eli Lilly. Su amplia experiencia incluye roles ejecutivos en recursos humanos y operaciones farmacéuticas.
Actualmente, Connelly forma parte de las juntas de Macy's y Lincoln Financial Group, y es la Presidenta de la Junta en Genmab A/B. Este nombramiento está alineado con la estrategia de Sarepta para ofrecer terapias transformadoras para enfermedades raras, aprovechando el liderazgo experimentado y la pericia de la industria de Connelly.
Sarepta Therapeutics (NASDAQ:SRPT)는 Deirdre P. Connelly를 이사회에 임명하여 이사회 멤버를 아홉 명으로 확장했으며, 그 중 여덟 명은 독립적입니다. Connelly는 GlaxoSmithKline의 북미 제약 부문 사장 및 Eli Lilly의 미국 제약 운영 사장을 역임하며 30년 이상의 제약 산업 경험을 가지고 있습니다. 그녀의 폭넓은 배경에는 인사 및 제약 운영 분야의 임원 역할이 포함되어 있습니다.
현재 Connelly는 Macy's 및 Lincoln Financial Group의 이사로 활동하고 있으며, Genmab A/B의 이사회 의장입니다. 이 임명은 Connelly의 풍부한 리더십과 산업 전문성을 활용하여 희귀 질병에 대한 혁신적인 치료법을 제공하려는 Sarepta의 전략과 일치합니다.
Sarepta Therapeutics (NASDAQ:SRPT) a nommé Deirdre P. Connelly au sein de son Conseil d'Administration, élargissant ainsi le conseil à neuf membres, dont huit sont indépendants. Connelly apporte plus de 30 ans d'expérience dans l'industrie pharmaceutique, ayant été présidente de la branche pharmaceutique pour l'Amérique du Nord chez GlaxoSmithKline et présidente des opérations pharmaceutiques aux États-Unis chez Eli Lilly. Son vaste parcours comprend des postes de direction dans les ressources humaines et les opérations pharmaceutiques.
Actuellement, Connelly siège au conseil d'administration de Macy's et de Lincoln Financial Group, et est la présidente du conseil d'administration de Genmab A/B. Cette nomination est conforme à la stratégie de Sarepta visant à fournir des thérapies transformantes pour les maladies rares, tirant parti du leadership aguerri et de l'expertise de Connelly dans l'industrie.
Sarepta Therapeutics (NASDAQ:SRPT) hat Deirdre P. Connelly in seinen Aufsichtsrat berufen, wodurch der Vorstand auf neun Mitglieder erweitert wird, von denen acht unabhängig sind. Connelly bringt über 30 Jahre Erfahrung in der Pharmaindustrie mit, nachdem sie Präsidentin für Nordamerika bei GlaxoSmithKline und Präsidentin der Pharmabetriebe in den USA bei Eli Lilly war. Ihr umfangreicher Hintergrund umfasst Führungspositionen im Personalwesen und in den Pharmaoperationen.
Derzeit ist Connelly Mitglied in den Aufsichtsräten von Macy's und Lincoln Financial Group und Vorsitzende des Aufsichtsrats von Genmab A/B. Diese Ernennung steht im Einklang mit der Strategie von Sarepta, transformative Therapien für seltene Krankheiten anzubieten und dabei Connellys erfahrene Führung und Branchenkenntnis zu nutzen.
- Addition of an experienced pharmaceutical executive to the Board of Directors
- Expansion of the Board to nine members, with eight being independent
- Potential for fresh perspectives and insights from Connelly's 30+ years of industry experience
- Strengthening of leadership team to support company growth and strategy execution
- None.
- Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta’s Board
“Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we’re pleased to welcome her to the Sarepta Board of Directors as we work to deliver on our strategy to bring transformative therapies to patients with rare diseases,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors.
“It’s an honor to join Sarepta’s Board and contribute to the next phase of the Company’s growth,” said Ms. Connelly. “I’m inspired by Sarepta’s science-driven mission and look forward to working alongside the Sarepta team, who represent the best and brightest of our industry, and to building upon their extraordinary accomplishments to bring life-changing therapies to patients.”
Connelly retired as president, North America Pharmaceuticals for GlaxoSmithKline (GSK) in 2015, a role she had held since 2009. Prior to joining GSK, she was with Eli Lilly and Company, where she served as president,
Born in
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding Sarepta’s mission and potential to bring life-changing therapies to patients and the potential benefits of the addition of Deirdre Connelly to Sarepta’s Board.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its products to
Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916194458/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
Who is Deirdre Connelly and why was she appointed to Sarepta Therapeutics' Board?
How many members are now on Sarepta Therapeutics' (SRPT) Board of Directors?
What is Deirdre Connelly's background in the pharmaceutical industry?